NeoCytex is developing therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases. The product works by accelerating the production of healthy new cells from endogenous stem cells, enhancing the body's natural ability to heal itself. Also included in the NeoCytex research pipeline are regenerative drug candidates that accelerate healing from wounds, fractures, and muscle injuries.
